Notification
No new Notification messages
Zinka Logistics Solutions IPO is Open!
Apply for the Zinka Logistics Solutions IPO through UPI in just minutes.
Q2 FY'24-25 Results of Top Companies
Reliance, TCS, HDFC Bank & more: Explore key financial highlights from India's top quarterly results.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

Cipla Q2 Results FY24-25 Highlights: Cons Revenue at ₹7,051 Cr Up 9%, PAT at ₹1,303 Cr Surged 17% YoY

Listen to our Podcast: Grow your wealth and keep it secure.

0:00 / 0:00

Synopsis:

Cipla Limited has reported consolidated Q2 results for FY24-25, showcasing a steady rise in financial performance. The company recorded a revenue of ₹7,051 Cr, an 8.6% YoY increase, and a PAT of ₹1,303 Cr, marking a 16.9% growth. This growth is attributed to strong sales across segments, particularly in India and North America.

Key Highlights/Quick Insights

  • Total Revenue: ₹7,051 Cr (8.6% YoY growth)
  • EBITDA: ₹1,886 Cr, with an 11.6% YoY increase
  • PAT: ₹1,303 Cr, reflecting a 16.9% increase
  • EBITDA Margin: 26.7%, a 70 basis points rise
  • PAT Margin: 18.5%, an improvement of 130 basis points

CIPLA LTD

Trade

1499.75-5.84 (-0.38 %)

Updated - 14 November 2024
1517.00day high
DAY HIGH
1490.25day low
DAY LOW
1469089
VOLUME (BSE)

Quarterly Performance – Cipla Q2 Results FY24-25

Cipla’s quarterly performance has been buoyed by growth in domestic and North American markets, with substantial improvements in the chronic segment

Other Income:Expenses:

Metric

Q2 FY25

Q2 FY24

YoY % Change

Revenue from Operations

₹7,051 Cr

₹6,678 Cr

8.60%

EBITDA

₹1,886 Cr

₹1,689 Cr

11.60%

PAT

₹1,303 Cr

₹1,155 Cr

16.90%

EBITDA Margin

26.70%

26.00%

+70 bps

PAT Margin

18.50%

17.20%

+130 bps

Employee Benefits Expense

₹1,208 Cr

₹1,091 Cr

9%

Depreciation & Amortization

₹272 Cr

₹290 Cr

-6%

Segment Highlights

One India:North America:Africa and Emerging Markets:

Sector Expectations for Cipla 2Q Results FY24-25

Cipla's results align with sector expectations, especially in chronic therapies like respiratory and cardiac, where growth continues despite industry challenges. The management's strategic focus on high-growth markets has been instrumental in surpassing sector benchmarks.

Management Commentary

Cipla’s management expressed satisfaction with the quarter’s performance, attributing growth to strategic launches and robust demand in core therapeutic areas. The leadership emphasized continued investment in R&D and expansion across high-growth segments.

Check out Cipla's past performances in previous quarters and financial years. 

Conclusion

Cipla’s Q2 FY24-25 results underscore its growth trajectory in both domestic and international markets. With a strong pipeline, particularly in the North American generic segment, Cipla remains committed to sustainable growth. The company's strategic focus on key therapies and segments continues to drive value for stakeholders. 

Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.

This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

For All Disclaimers Click Here: https://bit.ly/3Tcsfuc

Share this article: 

Read More Blogs

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 Lacs + Users

icon-with-text

4.8+ App Rating

icon-with-text

4 Languages

icon-with-text

₹5000+ Cr MTF Book

icon-with-text